NewsBenzingaフレックス、第3四半期調整後EPSを1.19~1.25ドルと予想、予想の1.22ドルを上回る見通し 売上高は88.70億~91.70億ドルと予想、予想の89.53億ドルを上回る見通し フレックス、第3四半期調整後EPSを1.19~1.25ドルと予想、予想の1.22ドルを上回る見通し 売上高は88.70億~91.70億ドルと予想、予想の89.53億ドルを上回る見通し Benzinga 2026.10.28 11:12 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients